Skip to Content

MabCampath

Active Substance: alemtuzumab
Common Name: alemtuzumab
ATC Code: L01XC04
Marketing Authorisation Holder: Genzyme Europe B.V.
Active Substance: alemtuzumab
Status: Withdrawn
Authorisation Date: 2001-07-06
Therapeutic Area: Leukemia, Lymphocytic, Chronic, B-Cell
Pharmacotherapeutic Group: Antineoplastic agents

Therapeutic Indication

MabCampath is indicated for the treatment of patients with B-cell chronic lymphocytic leukaemia (BCLL) for whom fludarabine combination chemotherapy is not appropriate.

The marketing authorisation for MabCampath has been withdrawn at the request of the marketing-authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide